Florham Park, NJ, May 2nd, 2022
Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Progesterone Injection USP, 500 mg/10 mL (50 mg/mL) Multiple-Dose Vial, generic to Progesterone Injection USP, 50 mg/mL.
Annual market sales for Progesterone Injection USP, 50 mg/mL and its generics for the twelve month period ending February, 2022 were $20.4 million, according to IQVIA™.
Donna Genova, Senior Vice President of Sales & Commercial Operations commented, “This is Xiromed’s second US product launch from our dedicated hormonal injectable facility, Laboratorios Farmalan, located in Leon, Spain. Xiromed continues to execute on our strategy to bring a robust portfolio of hormonal injectable products to the US market.”
Xiromed LLC, located in Florham Park, NJ, is a US company of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/
